Equities

BioNeutra Global Corp

BGA:CVE

BioNeutra Global Corp

Actions
  • Price (CAD)0.08
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change+23.08%
  • Beta2.3524
Data delayed at least 15 minutes, as of Jun 21 2024 16:32 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioNeutra Global Corporation, through its subsidiaries, is involved in the research and development, production and commercialization of food ingredients for nutraceutical, functional and mainstream foods, with a focus on oligosaccharides. Its lead product, VitaFiber IMO is an advanced functional and health food ingredient naturally derived from agricultural products. VitaFiber IMO is naturally sweet and lower in calories than sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health. The Company produces VitaFiber IMO using its patented production processes that naturally transform starch molecules from agriculture cereal crops including tapioca, field pea or corn into the functional health molecules of isomalto-oligosaccharide (IMO). VitaFiber IMO is also available for retail purchase across the globe through Amazon.com and Shopify.com. Its customers include small and medium enterprises and food manufacturers.

  • Revenue in CAD (TTM)10.85m
  • Net income in CAD-2.02m
  • Incorporated1996
  • Employees--
  • Location
    BioNeutra Global Corp9608 - 25 Avenue NWEDMONTON T6N 1J4CanadaCAN
  • Phone+1 (780) 466-1481
  • Fax+1 (780) 466-1481
  • Websitehttps://www.bioneutra.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GLG Life Tech Corp8.99m-32.45m1.92m86.00------0.2137-0.8453-0.84530.234-4.950.41572.594.05104,479.90-151.69-48.40----28.6420.60-364.90-126.250.0193-0.032----0.4186-10.84-39.43---48.21--
Greenspace Brands Inc15.35m-10.26m2.55m29.00------0.1659-0.0251-0.02520.0328-0.02551.023.076.22---68.39-40.10---68.6419.1719.16-66.86-44.740.1892-1.952.52---38.88-17.1550.68---36.34--
Organto Foods Inc26.94m-9.60m2.57m40.00------0.0956-0.338-0.3380.9474-0.28522.2988.5912.04673,388.30-81.71-77.98-237.87-208.698.096.79-35.63-54.890.6072-4.027.34--13.35106.27-70.77---6.43--
BioNeutra Global Corp10.85m-2.02m3.72m--------0.3426-0.0431-0.04310.2329-0.15060.65311.3411.62---12.13-18.99-243.67-59.5739.4013.69-18.58-23.540.1499-1.4912.43---15.00-21.3127.86---52.78--
Genix Pharmaceuticals Corp5.66k-4.08m4.15m--------732.45-0.0689-0.06890.0001-0.02170.00270.01080.6142---190.99-54.69-560.53-68.5969.08---72,076.33-5,345.880.0521-5.80-------50.60-309.27------
Data as of Jun 21 2024. Currency figures normalised to BioNeutra Global Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.